Researchers discover new therapeutic approach for cardiorenal syndrome type 2

15-Jun-2016 - A study suggests a new therapeutic approach to treat the development of chronic kidney disease secondary to chronic heart failure, known as cardiorenal syndrome type 2. In the journal's June 13 online edition, researchers at Cincinnati Children's Hospital Medical Center suggest inhibiting G ...

Actelion submits a NDA for macitentan for the treatment of patients with pulmonary arterial hypertension

23-Oct-2012 - Actelion announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for macitentan (Opsumit®) for the treatment of patients with pulmonary arterial hypertension.Macitentan, a novel oral dual endothelin receptor antagonist, was ...

Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease

23-Nov-2010 - Abbott announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease). Study results suggest ...

Key player identified in cascade that leads to hypertension-related kidney damage

09-Nov-2009 - A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel ...

Tracleer (bosentan) receives EU approval for pediatric formulation

The first and only licensed pulmonary arterial hypertension therapy for children

07-Jul-2009 - Actelion Ltd announced that the pediatric dispersible formulation of Tracleer® (bosentan) for the treatment of pulmonary arterial hypertension (PAH) in children has been approved in the European Union. This approval makes Tracleer® the only PAH therapy with an approved pediatric formulation for ...

Bosentan (Tracleer) receives positive CHMP opinion for pediatric formulation

28-Apr-2009 - Actelion Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for the pediatric formulation of bosentan (Tracleer®) for the treatment of pulmonary arterial hypertension (PAH). The ...

Actelion Pharmaceuticals Ltd - Bosentan receives positive EU opinion

30-Jun-2008 - Actelion Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for bosentan (Tracleer®) to extend its use in Pulmonary Arterial Hypertension (PAH). The CHMP recommended that the ...

Encysive Pharmaceuticals delays studies with selective endothelin receptor antagonist TBC3711

27-Mar-2006 - Encysive Pharmaceuticals announced that Encysive and the U.S. Food and Drug Administration (FDA) have placed TBC3711, the Company's next-generation selective endothelin receptor antagonist entering early clinical studies, on clinical hold. The hold is a result of an unusual finding following ...

Morphochem announces determination of the X-ray structure of Endothelin Converting Enzyme (ECE-1) complexed with Phosphoramidon

02-Dec-2005 - Morphochem AG has announced that they have successfully achieved an important milestone in their research collaboration with Solvay Pharmaceuticals using Morphochem's structural biology tools to support their Endothelin-Converting Enzyme inhibitor program. Morphochem applied its protein ...